The United States spends more on healthcare than any other country, and it’s not particularly close. In 2024, national health expenditures hit $5.3 trillion, or $15,474 per person, consuming 18% of the entire economy. That’s roughly double what most peer nations spend per capita. The reasons aren’t mysterious, but they are layered: higher prices for nearly everything, expensive drugs, massive administrative overhead, consolidated hospital markets, and a population carrying a heavy burden of chronic disease.
Prices Are Higher for the Same Services
The single biggest driver is price. Americans don’t use dramatically more healthcare than people in other wealthy countries. They just pay far more for the same procedures. A coronary bypass surgery costs $44,149 through Medicare and $89,094 through private insurance. The average across comparable countries is $24,847. That means even the government-negotiated Medicare price is nearly double what other nations pay, and private insurers pay more than triple.
The pattern holds across the board. A coronary angioplasty runs $34,504 through U.S. private insurance, compared to roughly $3,300 to $11,000 in peer countries. A cesarean section costs $13,601 with private coverage versus an average of $5,928 elsewhere. Even something as routine as a knee MRI costs $566 through private plans, nearly four times the $143 average in other countries. Medicare gets closer to international norms on imaging ($165 for that same MRI), but for major procedures, even Medicare prices tower above the rest of the world.
These gaps exist because most other wealthy nations use government-regulated pricing or single-payer systems that give them enormous bargaining power. In the U.S., prices are largely set through negotiations between individual insurers and providers, with little transparency and wide variation.
Prescription Drugs Cost Several Times More
Drug prices are one of the starkest examples. A 2022 analysis by RAND found that U.S. manufacturer prices for all prescription drugs were 278% of prices in 33 other OECD countries. For brand-name drugs specifically, U.S. prices were 422% of international prices. Even after adjusting downward by 37% to account for confidential rebates that drug companies pay to insurers and pharmacy benefit managers, brand-name drugs still cost 308% of what other countries pay.
There’s an interesting wrinkle: generic drugs are actually cheaper in the U.S. than abroad, running about 67% of international prices. Generics also account for 90% of prescriptions filled in America, compared to around 41% in other countries. But that volume advantage doesn’t offset the enormous premium on brand-name medications, which make up a disproportionate share of total drug spending. The core issue is that until recently, the U.S. government was prohibited from negotiating drug prices for Medicare. New provisions under the Inflation Reduction Act allow Medicare to negotiate prices on select high-cost drugs starting in 2026, with projected savings of $1.5 billion for Medicare Part D enrollees in the first year and an estimated $6 billion in net savings if those negotiated prices had applied to 2023 spending.
Administrative Costs Consume a Quarter of Spending
Between 20% and 25% of all U.S. healthcare dollars go to administration. That’s roughly $1 trillion a year spent not on patient care but on billing, coding, insurance processing, prior authorizations, claims management, and the bureaucratic infrastructure that keeps a fragmented system running. Every hospital, clinic, and physician’s office must navigate dozens of different insurance plans, each with its own rules, coverage criteria, and payment schedules. Insurers, in turn, maintain large staffs to process claims, deny claims, and handle appeals.
Countries with single-payer systems or tightly regulated multi-payer systems have far simpler billing. A hospital in Canada sends one bill to one payer. A hospital in the U.S. might deal with Medicare, Medicaid, a dozen commercial insurers, and patients paying out of pocket, each requiring different documentation. That complexity has a real cost, and it’s baked into every medical bill.
Hospital Consolidation Drives Up Private Insurance Prices
Over the past three decades, more than a thousand hospital mergers and acquisitions have reshaped the U.S. healthcare landscape. The stated goal is usually efficiency. The actual result, consistently documented in research, is higher prices. The Federal Trade Commission has found that merged hospitals charge 40% to 50% more than they would have without consolidation. When a hospital system becomes the dominant or only option in a region, private insurers lose leverage. They can’t exclude that hospital from their network, so they accept whatever price is demanded.
As the trade group for health insurers has put it: “Consolidation promises greater efficiency, but all that ever materializes is greater costs.” Studies of large HMO populations in California confirmed that hospital-owned systems incur significantly higher expenditures per patient than independent physician groups. Meanwhile, research shows that hospital competition actually improves quality of care, both in market-priced systems like U.S. private insurance and in fixed-price systems like Medicare. Consolidation removes that competitive pressure.
Chronic Disease Creates Ongoing Demand
Ninety percent of the nation’s $4.9 trillion in annual health expenditures (a figure from the year before spending rose to $5.3 trillion) goes toward people with chronic and mental health conditions, according to the CDC. The U.S. has higher rates of obesity, diabetes, and heart disease than most peer nations. These conditions require continuous management: medications, specialist visits, lab work, hospitalizations, and procedures that compound year after year.
This isn’t just a healthcare problem. It reflects decades of food policy, urban design, income inequality, and gaps in preventive care. But the financial impact is enormous. A person managing Type 2 diabetes, high blood pressure, and elevated cholesterol might see multiple specialists, take several medications, and undergo regular screenings indefinitely. Multiply that across tens of millions of people and the spending adds up fast, especially when each of those touchpoints is priced at American rates.
Physician Salaries Are Far Higher Than Elsewhere
U.S. physicians earn an average of $316,000 per year. In Germany, the next highest-paying country among major peers, the figure is $183,000. In the United Kingdom it’s $138,000. In France, $98,000. American doctors earn roughly double to triple what their counterparts make in other wealthy nations. Specialists in fields like orthopedics, cardiology, and dermatology often earn significantly more than that average.
These salaries partly reflect the cost of becoming a doctor in the U.S. Medical school debt regularly exceeds $200,000, residency training is long and grueling, and the liability environment is intense. But higher compensation also reflects the broader pricing dynamics of the system. When hospitals and health systems charge more, they can pay more. Physician pay accounts for a meaningful but not dominant share of total spending. It’s one piece of a larger pricing puzzle.
Defensive Medicine Adds Billions in Unnecessary Tests
Fear of malpractice lawsuits drives physicians to order tests and procedures they don’t believe are medically necessary. This practice, known as defensive medicine, is estimated to cost $46 billion annually. One hospital-based study found that about 13% of inpatient costs were defensive in nature, averaging $226 per patient admission. A survey of Massachusetts internists found that 27% of CT scans, 16% of lab tests, and 14% of hospital admissions were driven by liability concerns rather than clinical judgment.
The U.S. malpractice system is far more litigious than those in other countries. Malpractice insurance premiums for high-risk specialties like obstetrics and neurosurgery can exceed $100,000 a year, costs that get passed along to patients and insurers. The broader effect is a culture of over-testing that inflates spending without improving outcomes.
Why It All Compounds
No single factor explains American healthcare costs. The system is expensive because every layer is expensive simultaneously. Prices for procedures, drugs, and labor are all higher. Administrative waste consumes a quarter of total spending. Market consolidation removes competitive pressure on pricing. A sicker population generates more demand. And defensive medicine piles on unnecessary services. In countries that spend half as much per person, you typically find government-set prices, simpler administration, negotiated drug costs, and stronger primary care systems that manage chronic disease before it escalates. The U.S. has chosen a more market-driven approach, but without the transparency or competition that would normally keep prices in check.